Short answer
LB PHARMACEUTICALS INC (LBRX) filed an 8-K current report with the SEC on September 15, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Susan G. Kozauer appointed Chief Medical Officer effective September 14, 2026.
LB PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Susan G. Kozauer appointed Chief Medical Officer effective September 14, 2026
- Background includes clinical-development leadership at Centessa Pharmaceuticals and Intra-Cellular Therapies
- $515,000 annual salary, 40% target bonus, and $150,000 sign-on bonus
- Proposed inducement option for 200,000 shares, vesting over four years
- Nine months’ severance normally, with enhanced change-of-control protection including equity acceleration
Item 7.01 · Regulation FD Disclosure
- Dr. Kozauer appointed Chief Medical Officer, strengthening clinical and development leadership
- Appointment disclosed under Regulation FD; accompanying press release provides additional background and terms
Item EX-99.1 · Exhibit EX-99.1
- Susan G. Kozauer appointed Chief Medical Officer, strengthening clinical and regulatory leadership
- Prior CAPLYTA development experience spans schizophrenia, mood disorders, pediatric indications, and multiple FDA approvals
- Appointment arrives ahead of Phase 3 NOVA-2 schizophrenia topline results expected in the first half of 2027
- Kozauer will lead LB-102 development across multiple neuropsychiatric indications
- Key risks remain clinical, regulatory, funding, commercialization, and LB-102 execution dependence
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LB PHARMACEUTICALS INC 8-K filings
Get the next LBRX 8-K as it lands
Follow LBRX for push alerts, or ask the research agent what this filing means.